AXSM
$179.18-1.59%
as of close, Oct 2, 2026
☾ AH $179.18 -1.59%
Axsome Therapeutics Inc.Stock · Health CareNasdaq Composite 0.03%Russell 1000 0.02%US Stock Market 0.01%Russell 3000 0.01%
AXSM — Axsome Therapeutics Inc. price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
VolumeEEEE
50.0100.0150.0200.0250.0050.0M$179.18—20162019202120242026
2026-10-02
Price$179.18
MA20$218.76
MA50$175.64
Vol5.7M
Key stats
Price data
- Price
- $179.18
- Change YTD
- -1.89%
- Next earnings
- Nov 2, 2026
- Market cap
- 9.4B
- Enterprise value
- 9.3B
- Shares outstanding
- 52.4M
- 52W low
- $117.30
- 52W high
- $260.19
- From 52W high
- -31.13%
- From 52W low
- +52.75%
- 52W range
- 43%
- Beta
- 0.72
Volume
- Rel volume
- 1.31×
- 30D volume
- 661K
- 30D $ vol
- 133.2M
Insider trading
- Insider net 1W
- none
- Insider net 1M
- none
- Insider net 3M
- −$12.6M
- Insider net 1Y
- −$100.9M
Form 4 transactions by trade date, as filed; latest on file 2026-09-03.
Fundamentals
- Sales (ttm)
- 776.6M
- Sales/share
- $14.83
- EPS (ttm)
- -$3.76
- FCF (ttm)
- -72M
- FCF/share
- -$1.37
- Book value/share
- $1.59
- Net margin
- -24.68%
- ROE
- -230.05%
- ROA
- -25.17%
- Debt / equity
- 1.42×
- Current ratio
- 1.43
Growth (CAGR, ttm) · 10Y
- Sales
- +56.92%+62.03%n/an/a
- Shares
- +4.97%+3.54%+6.81%+10.59%
Per-share growth (CAGR, ttm) · 10Y
- Sales/share
- +49.49%+56.49%n/an/a
- Book value/share
- +8.61%-35.43%-3.45%-1.35%
- Price
- +49.43%+38.90%+39.18%+36.65%
- Total return
- +49.43%+38.90%+39.18%+36.65%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- -47.6×
- Fwd P/E
- 39.1×
- P/S (ttm)
- 12.1×
- P/B (mrq)
- 112.7×
- EV/Sales (ttm)
- 12.0×
- FCF yield (ttm)
- -0.77%
- Buyback yield (realized, 1y)
- -4.97%
- Shareholder yield (realized, 1y)
- -4.97%
- Buyback yield (cash, ttm)
- -0.38%
- Shareholder yield (cash, ttm)
- -0.38%
Vs own 10Y history
- P/S
- 13th
- P/B
- 86th
Bar = where today’s multiple sits in AXSM’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).
Performance · price return · as of 2026-10-02
1D
-1.59%
5D
-8.16%
1M
-14.64%
3M
-26.66%
YTD
-1.89%
1Y
+49.39%
5Y
+422.70%
Recent filings
- Sep 3Insider sale · Jacobson Mark L. (Chief Operating Officer) sold 10,000 shares for $2.1M at $208.65 under a 10b5-1 plan
- Aug 10Earnings · Earnings release — EPS −$0.99 vs −$0.99 est. (+0.0%); revenue $218.4M (+46% y/y) 3.8%
- Aug 10Report · Quarterly report, Q2 2026 — revenue $218.4M (+46% y/y), net income −$51.3M, EPS −$0.99
- Aug 6Insider sale · TABUTEAU HERRIOT (Chief Executive Officer · Director · 10% owner) sold 4,660 shares for $997K at $213.95 under a 10b5-1 plan
- Aug 5Insider sale · TABUTEAU HERRIOT (Chief Executive Officer · Director · 10% owner) sold 45,004 shares for $9.5M at $212.01 under a 10b5-1 plan
Financial statements
Open full AXSM financials →Loading financial statements…
Related Health Care
| Ticker | Name | 1M | 1D |
|---|---|---|---|
| NVS | Novartis AG | -13.21% | -0.04% |
| NVO | Novo Nordisk A/S | -20.21% | -0.21% |
| SNY | Sanofi ADS | -10.23% | -1.84% |
| GSK | GSK plc American Depositary Shares (Each representing two Ordinary Shares) | -6.76% | -0.32% |
| NTRA | Natera Inc. | +26.20% | +0.46% |
| ARGX | argenx SE American Depositary Shares | -12.90% | -1.79% |
| TAK | Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) | -3.09% | +0.00% |
| TEVA | Teva Pharmaceutical Industries Limited American Depositary Shares | +5.44% | +0.56% |
